Understanding harmful cells in lung scarring
Official title: Cellular and molecular delineation of pathologic fibroblasts in pulmonary fibrosis
Funded at University of California, San Francisco · NIH-10885214 · Data updated 2026-11-12
This study is looking at certain cells in the lungs that cause scarring in pulmonary fibrosis, and by using special techniques, researchers hope to learn more about these cells to find better ways to treat the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 10, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $248,947 |
| NIH project number | 5R00HL155786-04 |
| Project ID | NIH-10885214 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary fibrosis, particularly those experiencing significant lung function decline.
✕Less likely to help
Patients with other forms of lung disease or those without a diagnosis of pulmonary fibrosis may not benefit from this research.
What this research studies
This research investigates the role of specific fibroblast cells that contribute to lung scarring in pulmonary fibrosis, a serious lung disease. By using advanced techniques like single-cell RNA sequencing, the study aims to identify and characterize these pathologic fibroblasts, which are responsible for excessive collagen production. The researchers have developed a unique mouse model to manipulate these cells and better understand their behavior and impact on lung function. This knowledge could lead to new therapeutic strategies to target and treat pulmonary fibrosis more effectively.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that specifically target harmful fibroblast cells, potentially improving outcomes for patients with pulmonary fibrosis.
How similar studies have gone: Previous research has shown promise in targeting specific cell types in fibrotic diseases, suggesting that this approach could yield significant insights and advancements.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Tsukui, Tatsuya — University of California, San Francisco
- Study coordinator: Tsukui, Tatsuya
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.